Roche and Zealand Pharma reported midstage results for petrelintide showing a mean placebo‑controlled weight loss of about 9% (10.7% absolute) at 42 weeks—below investor expectations and well under the early performance of Eli Lilly’s comparator candidate. The readout triggered a sharp share decline for Zealand as analysts warned the drug may struggle to differentiate in a crowded obesity market. Zealand emphasized the combination of tolerability and efficacy supports progression to a Phase III program, while market watchers highlighted the competitive pressure from higher‑efficacy GLP‑1 and amylin programs. The data also suggest a potential ceiling on weight loss gains at higher doses for petrelintide. The result reinforces the challenge for second‑wave obesity therapeutics to match Lilly’s efficacy benchmarks; developers will need either superior tolerability or distinct clinical advantages to capture market share.